About MagForce AG: MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company`s proprietary procedure, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit http://www.magforce.com.
Disclaimer: This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
Contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Magforce AG Max-Dohrn-Str. 8 10589 Berlin T +49 30 308 380 31 F +49 30 308 380 99 M +49 151 12000 722 email: swiedenmann@magforce.com
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE HUG#1589846
Follow this link:
MagForce AG Successfully Completes Capital Increase